newsfilter
← Latest News
GlobeNewswire·

Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting

MONTREAL and CHARLOTTE, N.C., June 16, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) today announced submission of its response to the U.S. Food and Drug Administration (FDA)'s Complete